Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer
treatment, and it has achieved unprecedented success in hematological malignancies …

Nine new fluorine-containing drugs have been approved by the US Food and Drug
Administration (FDA) in 2021, which are presented in this review article. These small …

Background Sinonasal neoplasms, whether benign and malignant, pose a significant
challenge to clinicians and represent a model area for multidisciplinary collaboration in …

In recent years, Bruton tyrosine kinase (BTK) inhibitors have provided significant advances
in the treatment of patients with B-cell malignancies. Ibrutinib was the first BTK inhibitor to be …

We evaluated the global patterns of non‐Hodgkin lymphoma (NHL) in 2020 using the
estimates of NHL incidence and mortality in 185 countries that are part of the GLOBOCAN …

Non-Hodgkin lymphomas represents a heterogeneous group of lymphoproliferative
disorders characterized by different clinical courses, varying from indolent to highly …

Mantle cell lymphoma is a rare B-cell non-Hodgkin lymphoma that is clinically and
biologically heterogeneous. Risk stratification at the time of diagnosis is critical. One of the …

This Guideline was compiled according to the BSH process at https://bs-41 h. org.
uk/media/16732/bsh-guidance-development-process-dec-5-18. pdf and 42 represents best …

The SCHOLAR-5 study examines treatment patterns and outcomes of real-world follicular
lymphoma (FL) patients on 3 rd line of treatment (LoT) or higher, for whom existing data are …

The phase 3 SELENE study evaluated ibrutinib+ chemoimmunotherapy (CIT; bendamustine
and rituximab [BR]; or rituximab, cyclophosphamide, doxorubicin, vincristine, and …